Biopharma giants Amgen Inc. and Eli
Lilly earlier this month announced an antibody manufacturing collaboration for potential COVID-19 treatments, in an effort to scale up production for multiple treatments still in development.
The collaboration between Thousand Oaks-based Amgen and Lilly, headquartered in Indianapolis, will significantly boost global supply capacity for Lilly’s COVID treatments, the companies said.

Join our Membership to get the full story.

Are you a current Member? Sign In